À Propos de l'Entreprise
- Raison sociale: Regenix drugs Ltd
- Pays d'enregistrement: India
- Adresse: B-26, Phase -II, Zone B ,MEPZ -SEZ, Tambaram, , Tamilnadu
- Nombre d'employés: 50 - 99
- Année de création: 2007
Description:
Regenix is a biosimilar injection formulation and fill-finish manufacturing facility located in Chennai, India. A WHO-GMP-accredited, state-of-the-art facility spanning 30,000 square feet, designed to the latest GMP regulatory standards to fill sterile products in vials, pre-filled syringes and cartridges, the company's current CTD-format dossier product list includes human insulin injection (R, 30/70 and NPH), Insulin Glargine, Liraglutide and Enoxaparin Sodium injections.
Activités Commerciales
Formes Pharmaceutiques Finies
Fabricant
Produits Biopharmaceutiques
Fabricant
Classification ATC (Anatomique, Thérapeutique, Chimique)
Fabricant
Marchés de Vente
- South Asia: Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan, Sri Lanka, Afghanistan, Iran
- Mainland Southeast Asia: Cambodia, Lao People's Democratic Republic, Myanmar, Thailand, Viet Nam, Brunei Darussalam, Indonesia, Malaysia, Philippines, Timor-Leste, Singapore
- Northern Europe: Iceland, Norway, United Kingdom
- Southern Europe: Albania, Andorra, Bosnia and Herzegovina, North Macedonia, Montenegro, Serbia, Vatican City
Produits/Services Clés
- Formes Pharmaceutiques Finies: Similin® 30(insulin human 30 injection)
- Produits Biopharmaceutiques: Biosimilar injectables
- Classification ATC (Anatomique, Thérapeutique, Chimique): Insulin Glargine injection 100IU/Ml, Liraglutide injection 6mg/ml (rDNA origin), Insulin Injection soluble (Regular), Biphasic isophane insulin injection (30/70), Isophane Insulin Injection (rDNA origin)
Nos Produits & Services
Certifications
GMP
ISO
Proofs
CPHI Milan 2026
10/2026 – 10/2026
CPHI Milan 2026
Évaluations
(0)
(0)
(0)
(0)
(0)
Commentaires
Filtres :
Trier par :
Aucun commentaire disponible.
Laissez votre note & commentaire